Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Latanya Benjamin

Pediatric Dermatology Davie, FL Medical Doctor

NPI 1417167057 CMS profile 403176

5200 S University Dr Ste 102, Davie, FL 33328

Open in the dashboard

General payments

$453,305

505 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Latanya Benjamin of Davie, FL is reported in the CMS Open Payments database as having received $453,305 across 505 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $95,763 111
2024 General $132,014 131
2023 General $56,588 80
2022 General $44,676 50
2021 General $14,524 12
2020 General $8,621 12
2019 General $101,120 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Latanya Benjamin
  • Pediatric Dermatology median
  • Middle half of Pediatric Dermatology
  • National median

In program year 2025, general payments to Latanya Benjamin were reported at $95,763. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.

Show as a table
Year Latanya Benjamin Pediatric Dermatology median Middle half National median
2019 $101,120 $280 $89–$1,853 $163
2020 $8,621 $263 $71–$2,376 $114
2021 $14,524 $227 $69–$1,800 $132
2022 $44,676 $289 $69–$1,516 $149
2023 $56,588 $537 $114–$3,255 $160
2024 $132,014 $437 $114–$2,693 $164
2025 $95,763 $302 $110–$2,128 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $118,082 162 payments
  2. Genzyme Corporation $111,874 71 payments
  3. Incyte Corporation $43,860 55 payments
  4. Arcutis Biotherapeutics, Inc. $37,328 34 payments
  5. Verrica Pharmaceuticals Inc. $35,597 33 payments
  6. Pfizer Inc. $30,414 36 payments
  7. Organon LLC $26,878 23 payments
  8. Dermavant Sciences, Inc. $14,040 1 payment
  9. Regeneron Pharmaceuticals, Inc. $10,015 3 payments
  10. Eli Lilly and Company $8,400 2 payments
  11. Other $16,818 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $248,988 66 payments
  2. Consulting Fee $108,976 28 payments
  3. Travel and Lodging $51,744 133 payments
  4. Honoraria $27,950 9 payments
  5. Food and Beverage $14,128 266 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,500 1 payment
  7. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $121,778 141 payments
  2. DUPIXENT Immunology $109,009 67 payments
  3. OPZELURA $43,842 54 payments
  4. VTAMA $40,918 24 payments
  5. YCANTH $35,597 33 payments
  6. Zoryve $35,028 32 payments
  7. DUPIXENT Immunology $33,550 22 payments
  8. EUCRISA $13,149 15 payments
  9. EBGLYSS $8,446 4 payments
  10. CIBINQO $6,456 12 payments
  11. Other $12,871 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

505 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record